Sanofi (SNY) Accounts Payables (2009 - 2026)

Sanofi has disclosed Accounts Payables across 18 years of filings, most recently posting $8.3 billion for Q2 2026.

• In Q2 2026, Accounts Payables rose 3.77% year-over-year to $8.3 billion; the TTM figure through Jun 2026 stood at $8.3 billion (up 3.77% YoY), while the FY2025 annual figure was $8.6 billion, up 4.84% from the prior year.
• Accounts Payables came in at $8.3 billion for Q2 2026 at Sanofi, down from $8.6 billion in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $8.6 billion in Q4 2025 to a low of $7.0 billion in Q4 2022.
• Average Accounts Payables over 5 years is $7.9 billion, with a median of $8.0 billion recorded in 2025.
• Year-over-year, Accounts Payables dropped 1.68% in 2022 and advanced 14.61% in 2023.
• Over 5 years, Accounts Payables stood at $7.0 billion in 2022, then gained by 13.43% to $7.9 billion in 2023, then rose by 2.34% to $8.1 billion in 2024, then climbed by 6.19% to $8.6 billion in 2025, then retreated by 3.01% to $8.3 billion in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $8.3 billion in Q2 2026, $8.6 billion in Q4 2025, and $8.0 billion in Q2 2025.